Description: Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars—first, a proprietary machine learning-based platform, Gritstone EDGE™, which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient’s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients’ TSNA to drive the patient’s immune system to attack and destroy tumors.
Home Page: gritstonebio.com
GRTS Technical Analysis
5959 Horton Street
EmeryVille,
CA
94608
United States
Phone:
510 871 6100
Officers
| Name | Title |
|---|---|
| Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D. | Co-Founder, Pres, CEO & Director |
| Mr. Erin E. Jones M.S. | Exec. VP & COO |
| Dr. Karin Jooss Ph.D. | Exec. VP and Head of R&D |
| Ms. Vassiliki Economides | Exec. VP & CFO |
| Mr. James Cho | Chief Accounting Officer |
| Ms. Stacy Proctor | Sr. VP & Head of People |
| Dr. Matthew J. Hawryluk M.B.A., Ph.D. | Exec. VP & Chief Bus. Officer |
| Mr. Vijay Yabannavar Ph.D. | Exec. VP & Chief Technical Devel. Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.59 |
| Price-to-Sales TTM: | 15.92 |
| IPO Date: | 2018-09-28 |
| Fiscal Year End: | December |
| Full Time Employees: | 193 |